Pretransfusion Testing: ABO, Antibody Investigation, and Compatibility

Pretransfusion compatibility begins with the correct recipient and specimen. The transfusion service then compares current ABO, D, and antibody results with the historical record before selecting and verifying a red-cell unit. Even technically correct testing cannot compensate for a specimen collected from the wrong person.

Identity, specimen, and history

Written procedures govern each step from the request through issue. At collection, staff identify the recipient with two independent identifiers, label the specimen in the recipient’s presence, and record the information required by policy. The request and specimen label must agree; any discrepancy or doubt about identity requires another specimen.^1,2,3

Federal compatibility-testing rules require a fresh recipient serum or plasma specimen that is less than 3 days old when the recipient was pregnant or transfused during the preceding 3 months. FDA guidance counts the collection date as day 0 and expires the specimen at midnight on day 3. Current AABB standards apply the same 3-day limit when the history is uncertain or unavailable in facilities that have adopted those standards. A longer interval for a patient with a reliable negative history requires a defined facility policy and must remain within the reagent instructions for use.^2,3,4,11

Before issue, the transfusion service compares the current record with previous ABO and D results, typing difficulties, clinically significant antibodies, transfusion reactions, and special component requirements. A clinically significant antibody history continues to govern unit selection after the antibody falls below the current method’s detection limit.^3,5

ABO and D assignment

Forward grouping tests recipient red cells with anti-A and anti-B. Reverse grouping tests recipient serum or plasma with A₁ and B reagent red cells. CLIA requires concurrent testing of patient red cells with anti-A and anti-B and confirmation of the ABO interpretation with A₁ and B cells. Because reaction grade varies with the reagent, cell concentration, method, and instrument, expected results are listed as positive or negative rather than at fixed strengths.^1,3

Expected ABO antibodies are unreliable in young infants. Circulating antibodies may be maternal, and the infant’s own response is still developing. Neonatal testing therefore follows the current infant and maternal-antibody procedure, which generally assigns ABO from forward grouping and uses maternal or infant plasma for the antibody evaluation as specified by the laboratory.⁵

ABO discrepancies

The laboratory must resolve a mismatch before assigning an ABO group. The current specimen, prior records, transfusion or transplant history, reaction grade, and microscopic appearance help classify the finding into one of several practical categories.^3,5

First verify identity and technique. Then repeat or extend testing under the laboratory procedure and the reagent instructions. If red cells are needed before the discrepancy is resolved, an emergency policy based on adopted AABB standards uses group O red cells while the investigation continues.³

D typing

D typing uses licensed anti-D reagent. The reagent instructions specify the method, required control, D-variant reactivity, and interpretation. A positive patient diluent or Rh-control reaction invalidates the D result and requires investigation under those instructions.^1,6

Donor and recipient weak-D policies answer different questions. Federal rules require additional testing, including weak D, before donor Whole Blood with an initially nonreactive anti-D test can be labeled Rh negative. AABB standards allow facilities that have adopted those standards to omit weak-D testing for recipients. When a serologic weak-D phenotype is detected in a pregnant patient or another female of childbearing potential, the AABB/CAP joint work group recommends RHD genotyping. Weak-D types 1, 2, and 3 can be managed as D positive under that recommendation; other or unresolved variants follow the transfusion service’s approved D-allocation and Rh immune globulin policy.^3,7,8

Unexpected-antibody detection

The antibody screen tests recipient serum or plasma against group O reagent red cells with known antigen profiles. Federal reagent rules require each lot of group O screening or identification cells to include D, C, E, c, e, K, k, Fy^a, Fy^b, Jk^a, Jk^b, Le^a, Le^b, P1, M, N, S, and s across the lot. Patient tests use individual, nonpooled cells, and the lot profile lists the antigens expressed by each cell.^3,9

Screening cells help detect dosage, a pattern in which an antibody reacts more strongly with cells that have greater antigen expression. Kidd, Duffy, MNS, and some Rh or Lutheran antibodies may show this pattern. A phenotype such as Jk(a+b−) suggests double-dose expression, although the manufacturer may be unable to establish the donor’s genotype. Interpret the current lot profile and its limitations exactly as labeled.^5,10

Screen interpretation depends on the validated method’s endpoint. In tube testing, a positive result may be agglutination or hemolysis; column and solid-phase systems have method-specific endpoints. A nonreactive screen means that the specimen has no antibody detectable against the antigens carried by those cells under those test conditions. Low antibody concentration, dosage, an antigen absent from the lot, or method limitations can still produce a nonreactive screen. Historical antibody findings therefore remain part of the compatibility decision.^5,10

Tube, column-agglutination, and solid-phase systems use different cell concentrations, enhancement media, incubation conditions, endpoints, and controls. Conventional tube antiglobulin testing requires adequate washing and IgG-coated control cells for a valid negative reaction. Card and solid-phase methods use their own manufacturer-specified controls. The laboratory validates the chosen system and follows its instructions for use.^1,5,10

Antibody investigation

An approved identification panel provides a broader set of antigen profiles for comparing reactions. Selected cells can supplement the panel. The investigation must identify clinically significant reactivity and exclude additional specificities that could change unit selection. An antibody is clinically significant if it can shorten the survival of antigen-positive red cells, cause a hemolytic transfusion reaction, or cause hemolytic disease of the fetus and newborn.^3,5

1. Review the transfusion, pregnancy, medication, transplant, and antibody history. Record the phase, grade, method, hemolysis, and any mixed-field reaction.
2. Compare reactive and nonreactive cells against the complete lot-specific antigen profile. Identification panels use group O cells so ABO antibodies do not obscure the comparison.
3. Test an autocontrol when it can clarify autologous reactivity, and perform a direct antiglobulin test when in-vivo coating is suspected. These results support the interpretation but do not prove antibody origin by themselves.
4. Exclude a candidate only with suitable nonreactive antigen-positive cells. Use documented double-dose cells for specificities that commonly show dosage, according to the laboratory’s validated exclusion rule. Low-prevalence antigens require selected cells when the panel does not supply enough informative examples.
5. Support the remaining specificity with multiple reactive antigen-positive cells and nonreactive antigen-negative cells. The common three-positive and three-negative convention is a teaching and laboratory-practice rule often used to support a probability of 0.05 or less under its statistical assumptions. Panel composition, antigen frequency, and local policy govern the final support.
6. Confirm that the recipient can form the proposed alloantibody. A valid phenotype should lack the corresponding antigen. Recent transfusion, a positive DAT, weak antigen expression, or mixed red-cell populations can make serologic phenotyping unreliable, so genotyping or reference-laboratory testing may be needed.
7. Select units according to the complete current and historical antibody record, then perform the required crossmatch.^3,5

Use reaction phase and thermal range to choose the next step. Reactivity at 37°C or the antiglobulin phase is more likely to affect transfusion support. Cold-phase reactivity requires evaluation of its thermal range, specificity, and ability to interfere with ABO or antiglobulin testing. These findings guide the investigation but do not identify an antibody by themselves.⁵

Pattern-based problem solving

A broad autoantibody may react with every available unit. The laboratory must still exclude clinically significant alloantibodies and provide antigen-negative units for any that are found. Residual autoantibody reaction grades do not rank unit safety. Urgent transfusion follows the approved emergency process while the investigation continues.⁵

Worked panel

A recipient’s antibody screen reacts at the antiglobulin phase. Testing six selected panel cells produces this simplified pattern:

The autocontrol is nonreactive. All three E-positive cells react, and all three E-negative cells are nonreactive. In this simplified example, nonreactive K-positive and Jk^a-positive cells help exclude anti-K and anti-Jk^a. A valid recipient phenotype is E negative. The pattern supports anti-E, so the laboratory selects E-negative red-cell units and performs an antiglobulin crossmatch. A real panel requires evaluation of every antigen on the full profile and every unexcluded clinically significant specificity.⁵

Unit selection and availability

Current or historical clinically significant antibodies require red-cell units that lack the corresponding antigen and meet the applicable serologic crossmatch requirement. Laboratory policy may allow crossmatch-compatible units for antibodies judged clinically insignificant through validated testing and history. That judgment considers specificity, reaction temperature, phase, method, history, and evidence of hemolysis.^3,4

Antigen frequencies help estimate the size of a compatible-unit search. When the frequencies are independent, multiply the negative fractions and divide the number of units required by the combined fraction. If validated donor data estimate that 91% of units lack antigen X and 27% lack antigen Y, the estimated compatible fraction is 0.91 × 0.27 = 0.246. Finding 3 units would require screening about 3 ÷ 0.246 = 12.2, so inventory planning would start with 13 units. Local donor data, antigen linkage, and previous donor typing refine this average estimate, which does not guarantee three compatible units.⁵

Red-cell ABO selection follows the recipient’s established group and the emergency or inventory policy. The table applies only to red-cell components; plasma and Whole Blood have separate compatibility rules.³

Crossmatch and issue

The crossmatch is the final compatibility step between recipient serum or plasma and a selected donor red-cell unit. The antibody result and history determine the required method.^3,11

Before transfusion, the transfusion service confirms the ABO group of each Whole Blood or red-cell unit. For a unit labeled D negative, it also confirms D from an attached segment. The transfusing facility does not need to repeat weak-D testing of the unit. A unit with a discrepant result remains quarantined from issue until the collecting facility resolves it.³

An immediate-spin crossmatch detects ABO incompatibility. An antiglobulin crossmatch can detect clinically significant IgG reactivity against donor cells. The ABO-only pathway requires both a nonreactive current antibody screen and no history of a clinically significant antibody. An antibody to a low-prevalence antigen carried by one donor may still produce an incompatible serologic crossmatch after a nonreactive screen.^3,5

Electronic crossmatch

Electronic crossmatch uses validated computer decision rules to determine ABO compatibility without mixing recipient plasma and donor cells. FDA guidance recommends verification of recipient identity, current ABO and D interpretation, antibody assessment and history, specimen information, special requirements, and donor-unit data. It also recommends a second confirmed ABO and D determination, preferably from a prior record or a separately collected specimen. Under that guidance, an ABO discrepancy, a current clinically significant antibody, or a history of one excludes the recipient from electronic crossmatch and requires serologic compatibility testing. Facilities implement the pathway under applicable law and their adopted standards.^3,11

Special circumstances

Emergency release. Federal rules require a procedure to expedite transfusion during a life-threatening emergency and preserve complete, physician-signed justification. Collect a pretransfusion specimen before infusion when the situation permits. Group O red cells can support an unknown ABO group; group-specific or ABO-compatible units can follow once testing establishes the group. Complete compatibility testing promptly and communicate any result that changes support.^2,3

Infant testing. For an infant younger than 4 months, follow the neonatal protocol for specimen validity, forward ABO grouping, maternal antibody history, and selection of red cells compatible with clinically significant maternal or infant antibodies. When a relevant antibody is present, the units must be antigen negative and antiglobulin compatible.⁵

Autologous units. Pretransfusion testing includes ABO and D testing of the patient specimen. The unit’s label and testing status must match its intended use and collection setting. A unit restricted to the donor-patient carries the required autologous-use identification.^3,12

Inventory planning and final verification

A type and screen establishes ABO, D, and antibody status before a transfusion is certain. A crossmatch order identifies units for intended transfusion. A maximum surgical blood order schedule uses the institution’s actual procedure-specific transfusion experience to set realistic orders. These tools limit unnecessary inventory reservations and preserve the longer preparation time needed for recipients with clinically significant antibodies.⁵

At issue, staff verify the recipient’s two independent identifiers, donation identification number, component, compatibility interpretation, special requirements, and expiration. Under the administration policy, the final bedside check matches the intended recipient to the compatibility record and component label. These checks maintain the link between the collected specimen, intended recipient, compatibility record, and issued component.³

References

1. Standard: Immunohematology, 42 CFR §493.1271 (2026). Accessed August 29, 2026.
2. Compatibility testing, 21 CFR §606.151 (2026). Accessed August 29, 2026.
3. Association for the Advancement of Blood & Biotherapies. Fundamental Standards for Blood Collection and Transfusion. 2nd ed. AABB; 2025. Effective January 1, 2026.
4. Association for the Advancement of Blood & Biotherapies. Standards for Blood Banks and Transfusion Services. 35th ed. AABB; 2026. Effective April 1, 2026.
5. Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026.
6. Bio-Rad Laboratories, Inc. Seraclone Anti-D Blend Blood Grouping Reagent Instructions for Use. US Food and Drug Administration. Accessed August 29, 2026.
7. Testing the blood, 21 CFR §640.5 (2026). Accessed August 29, 2026.
8. AABB, College of American Pathologists, American College of Obstetricians and Gynecologists, et al. Joint Statement on Phasing-In RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential With a Serologic Weak D Phenotype. 2015. Accessed August 29, 2026.
9. Testing of source material, 21 CFR §660.33 (2026). Accessed August 29, 2026.
10. Immucor, Inc. Panoscreen Reagent Red Blood Cells Package Insert. US Food and Drug Administration. Accessed August 29, 2026.
11. US Food and Drug Administration. Computer Crossmatch: Computerized Analysis of the Compatibility Between the Donor's Cell Type and the Recipient's Serum or Plasma Type. Guidance for Industry. April 2011.
12. AABB, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. June 2024.